Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663082 | 0.90 | PARP1 (0.57) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL666402 | 0.90 | PARP1 (0.57) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL662615 | 0.86 | PARP1 (0.62) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL665549 | 0.82 | PARP1 (0.57) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL663560 | 0.82 | PARP1 (0.57) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL12890049 | 0.82 | PARP1 (0.57) | POLBPARP1PKMBCHEACHE | |
| SCHEMBL20715553 | 0.80 | HTR2B (0.50) | POLB | |
| SCHEMBL18536605 | 0.80 | POLB (0.44) | POLBPKM | |
| SCHEMBL15458224 | 0.79 | BCHE (0.48) | POLBPKMBCHEACHEUSP30 | |
| SCHEMBL13243466 | 0.79 | ALDH1A1 (0.52) | POLBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120190720-A1 | Combination Therapy With Parp Inhibitors | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | ABBOTT LABORATORIES | 2008-11-27 | — | — | US | disclosed |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | ABBOTT LABORATORIES | 2007-11-15 | — | — | US | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 109/4885PARP1 2/4885PKM 465/4885 |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 109/4885PARP1 2/4885PKM 465/4885 |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | PARP1, PARP2, PARP3 | POLB 54/4885PARP1 1/4885PKM 506/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | POLB 60/4885PARP1 1/4885PKM 726/4885 |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | PARP1, PARP2, BRCA1 | POLB 139/4885PARP1 1/4885PKM 408/4885 |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 109/4885PARP1 2/4885PKM 465/4885 |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | POLB 109/4885PARP1 2/4885PKM 465/4885 |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP1, PARP2, PARP12 | POLB 185/4885PARP1 1/4885PKM 333/4885 |
| US-20120190720-A1 | Combination Therapy With Parp Inhibitors | PARP2, PARP1, PARP3 | POLB 59/4885PARP1 2/4885PKM 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.